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We are grateful to Professor Fabbri for his consideration of
our paper1 and the document recently published by the
Italian Respiratory Societies.2 As Professor Fabbri, we also
believe that using FEV1/FVC<0.7 or <LLN as entry criteria
for clinical trials does not make a substantial difference,
because in most instances the number of subjects with
FEV1/FVC<0.7 but >LLN is very small.
3 The only problem
using the fixed ratio is the inclusion of subjects without
well documented COPD, thus potentially decreasing the
power of the study. To avoid this potential bias and to
make our trial comparable with others, we have included in
our study only patients satisfying both criteria. We
acknowledge that we did not use post-bronchodilator pre-
dicted values. Doing so, we may have excluded some COPD
subjects but this cannot have affected the results of the
study because all subjects included had COPD confirmed
functionally. Finally, we thank Professor Fabbri for his
suggestion to look at individual data to see if there are
discrepancies due to different selection criteria. However,
this cannot be the case in the present study because all
subjects satisfied both criteria. In summary, we think the
fixed FEV1/FVC ratio can still be used for clinical trials,
though it may be misleading in clinical practice as well as
epidemiology.
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